Anne Eden Evins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Eden Evins has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Gladys Pachas
Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States
7 shared publications - Randi Melissa Schuster
Center for Addiction Medicine, Department of Psychiatry Massachusetts General Hospital Boston MA USA
6 shared publications Corinne Cather
Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston
5 shared publications- Jodi M. Gilman
Massachusetts General Hospital
5 shared publications Gladys N. Pachas
Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston
4 shared publications- Kevin Potter
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts; Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-12
Implementing Proactive Smoking Cessation Induction Interventions in a Certified Community Behavioral Health Clinic: A Pilot Type 2 Hybrid Effectiveness-Implementation Study
Background: People with mental health and substance use disorders have a high prevalence of tobacco use. Community mental health clinics, including certified behavioral health clinics, are a key entry point where people with mental health and substance use disorders receive care. Implementation strategies to deliver tobacco use disorder treatment in community health clinics are needed. Two promising strategies supported by clinical practice guidelines are proactive outreach (reaching out to people in a health system who smoke and providing treatment) and the 5As (mental health providers ask about tobacco use, advise to quit, assess interest in quitting, assist with cessation, and arrange for follow up). Methods: The current study is a pilot type two hybrid effectiveness-implementation trial conducted in a certified behavioral health clinic. The clinic received a multilevel implementation strategy comprising didactic training, performance feedback and organizational coaching to promote delivery of the 5As at intake and treatment planning visits. Clients of the organization who consented to the study also received three proactive outreach contacts over nine months offering connections to cessation counseling and medication. Clients completed study surveys at pre-implementation, implementation launch, and at 3-, 6- and 12-months post implementation launch. Providers completed surveys before and after training and at 3-, 6-, 9-, and 12-months post-training. Primary outcomes were feasibility and acceptability of the client intervention and organization implementation strategies. Secondary outcomes were preliminary indicators of patient effectiveness. Results: Client recruitment, intervention delivery, and study assessment were feasible, with 49 client participants recruited over 3 months. Outreach completion rates were higher for earlier calls and ranged from 67-94%. Retention was high with 84% of client participants completing the primary outcome assessment. The implementation strategy was also successful, with greater than 50% attendance at study trainings (77 of 125 providers attended), and feasible delivery of organizational coaching (coaching delivered to all 3 clinic sites) and performance feedback (all 3 clinic sites receiving monthly performance feedback). Acceptability ratings were high for both the intervention and the implementation strategy. Staff survey completion waned over time (completion rates 51-72%) and turnover was high. Client CO-confirmed abstinence rate at 12 months post enrollment was 8%. Conclusions: Implementing proactive tobacco use disorder treatment in a certified community behavioral health clinic was feasible and acceptable. A full scale trial to test the effectiveness of the study interventions and implementation strategy is warranted.
- 21 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-12
Open AccessImplementing Proactive Smoking Cessation Induction Interventions in a Certified Community Behavioral Health Clinic: A Pilot Type 2 Hybrid Effectiveness-Implementation Study
Background: People with mental health and substance use disorders have a high prevalence of tobacco use. Community mental health clinics, including certified behavioral health clinics, are a key entry point where people with mental health and substance use disorders receive care. Implementation strategies to deliver tobacco use disorder treatment in community health clinics are needed. Two promising strategies supported by clinical practice guidelines are proactive outreach (reaching out to people in a health system who smoke and providing treatment) and the 5As (mental health providers ask about tobacco use, advise to quit, assess interest in quitting, assist with cessation, and arrange for follow up). Methods: The current study is a pilot type two hybrid effectiveness-implementation trial conducted in a certified behavioral health clinic. The clinic received a multilevel implementation strategy comprising didactic training, performance feedback and organizational coaching to promote delivery of the 5As at intake and treatment planning visits. Clients of the organization who consented to the study also received three proactive outreach contacts over nine months offering connections to cessation counseling and medication. Clients completed study surveys at pre-implementation, implementation launch, and at 3-, 6- and 12-months post implementation launch. Providers completed surveys before and after training and at 3-, 6-, 9-, and 12-months post-training. Primary outcomes were feasibility and acceptability of the client intervention and organization implementation strategies. Secondary outcomes were preliminary indicators of patient effectiveness. Results: Client recruitment, intervention delivery, and study assessment were feasible, with 49 client participants recruited over 3 months. Outreach completion rates were higher for earlier calls and ranged from 67-94%. Retention was high with 84% of client participants completing the primary outcome assessment. The implementation strategy was also successful, with greater than 50% attendance at study trainings (77 of 125 providers attended), and feasible delivery of organizational coaching (coaching delivered to all 3 clinic sites) and performance feedback (all 3 clinic sites receiving monthly performance feedback). Acceptability ratings were high for both the intervention and the implementation strategy. Staff survey completion waned over time (completion rates 51-72%) and turnover was high. Client CO-confirmed abstinence rate at 12 months post enrollment was 8%. Conclusions: Implementing proactive tobacco use disorder treatment in a certified community behavioral health clinic was feasible and acceptable. A full scale trial to test the effectiveness of the study interventions and implementation strategy is warranted.
- Open Access
Impact of cannabis co‐use on tobacco cessation
Open AccessImpact of cannabis co‐use on tobacco cessation
- Open Access
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2547799
Cannabis Use and Nicotine Vaping Cessation Outcomes
Importance: Cannabis use is prevalent among adolescents and young adults who vape nicotine. It is not known if cannabis use affects nicotine vaping cessation success. Objective: To assess whether baseline frequency of cannabis use or cannabis use disorder (CUD) symptom severity was associated with nicotine vaping cessation in a randomized clinical trial. Design, Setting, and Participants: This secondary analysis of a randomized clinical trial with youth who vaped nicotine recruited at a single site in Massachusetts from June 2022 to May 2024. The trial included 3 groups receiving 12 weeks of varenicline treatment and placebo (both double-masked, paired with counseling), as well as single-masked referral to texting-app–based nicotine vaping cessation support (enhanced usual care [EUC]). Eligible participants were aged 16 to 25 years who reported vaping nicotine regularly and did not smoke tobacco. Exposure: Baseline cannabis use was assessed via self-reported number of days of cannabis use per week and with Cannabis Use Disorder Identification Test (CUDIT) scores. Main Outcomes and Measures: Biochemically verified 7-day point prevalence nicotine vaping abstinence at week 12. Logistic regression models estimated associations between baseline cannabis use and vaping abstinence. Interaction terms were evaluated to examine whether cannabis use moderated the effect of varenicline on nicotine abstinence. Results: Among the 261 participants randomized to nicotine vaping cessation treatment (mean [SD] age, 21.5 [2.0] years; 139 female [53%]), 28% (73 participants) reported no past-month cannabis use, 38% (100 participants) reported using cannabis more than 0 and less than 4 d/wk, and 30% (78 participants) reported using cannabis 4 to 7 d/wk. Cannabis use frequency was not significantly associated with nicotine vaping cessation (eg, 4 to 7 d/wk use vs no use: adjusted odds ratio [aOR], 1.14; 95% CI, 0.51-2.57; overall P = .20). Nor did cannabis frequency modify the effect of varenicline (eg, abstinence varenicline vs placebo or EUC among those with 4 to 7 d/wk use: aOR, 8.47; 95% CI, 2.78-28.25; vs among those with no use: aOR, 5.60; 95% CI, 1.97-17.06; overall interaction P = .32). Findings were similar for CUD symptom severity. Conclusions and Relevance: Among adolescents and young adults attempting to reduce or stop nicotine vaping, baseline cannabis use was not associated with nicotine vaping abstinence. Varenicline proved helpful for nicotine vaping cessation regardless of cannabis use, indicating that co-use of cannabis may not represent a barrier to successful nicotine vaping cessation treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT05367492
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2547799
Open AccessCannabis Use and Nicotine Vaping Cessation Outcomes
Importance: Cannabis use is prevalent among adolescents and young adults who vape nicotine. It is not known if cannabis use affects nicotine vaping cessation success. Objective: To assess whether baseline frequency of cannabis use or cannabis use disorder (CUD) symptom severity was associated with nicotine vaping cessation in a randomized clinical trial. Design, Setting, and Participants: This secondary analysis of a randomized clinical trial with youth who vaped nicotine recruited at a single site in Massachusetts from June 2022 to May 2024. The trial included 3 groups receiving 12 weeks of varenicline treatment and placebo (both double-masked, paired with counseling), as well as single-masked referral to texting-app–based nicotine vaping cessation support (enhanced usual care [EUC]). Eligible participants were aged 16 to 25 years who reported vaping nicotine regularly and did not smoke tobacco. Exposure: Baseline cannabis use was assessed via self-reported number of days of cannabis use per week and with Cannabis Use Disorder Identification Test (CUDIT) scores. Main Outcomes and Measures: Biochemically verified 7-day point prevalence nicotine vaping abstinence at week 12. Logistic regression models estimated associations between baseline cannabis use and vaping abstinence. Interaction terms were evaluated to examine whether cannabis use moderated the effect of varenicline on nicotine abstinence. Results: Among the 261 participants randomized to nicotine vaping cessation treatment (mean [SD] age, 21.5 [2.0] years; 139 female [53%]), 28% (73 participants) reported no past-month cannabis use, 38% (100 participants) reported using cannabis more than 0 and less than 4 d/wk, and 30% (78 participants) reported using cannabis 4 to 7 d/wk. Cannabis use frequency was not significantly associated with nicotine vaping cessation (eg, 4 to 7 d/wk use vs no use: adjusted odds ratio [aOR], 1.14; 95% CI, 0.51-2.57; overall P = .20). Nor did cannabis frequency modify the effect of varenicline (eg, abstinence varenicline vs placebo or EUC among those with 4 to 7 d/wk use: aOR, 8.47; 95% CI, 2.78-28.25; vs among those with no use: aOR, 5.60; 95% CI, 1.97-17.06; overall interaction P = .32). Findings were similar for CUD symptom severity. Conclusions and Relevance: Among adolescents and young adults attempting to reduce or stop nicotine vaping, baseline cannabis use was not associated with nicotine vaping abstinence. Varenicline proved helpful for nicotine vaping cessation regardless of cannabis use, indicating that co-use of cannabis may not represent a barrier to successful nicotine vaping cessation treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT05367492
- 19 June 2025
- Published by Springer Nature
- p. 385-404
Cannabis Use and Psychiatric Symptoms in Adolescence
- 19 June 2025
- Published by Springer Nature
- p. 385-404
Cannabis Use and Psychiatric Symptoms in Adolescence
- Open Access
- 9 May 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12 (1) , e67670
Digital Integrated Interventions for Comorbid Depression and Substance Use Disorder: Narrative Review and Content Analysis
Background: Integrated digital interventions for the treatment of comorbid depression and substance use disorder have been developed, and evidence of their effectiveness is mixed. Objective: This study aimed to explore potential reasons for mixed findings in the literature on integrated digital treatments. We described the methodologies and core characteristics of these interventions, identified the presence of evidence-based treatment strategies, examined patterns across digital modalities, and highlighted areas of overlap as well as critical gaps in the existing evidence base. Methods: In June 2024, a literature search was conducted in Google Scholar to identify digital integrated interventions for comorbid major depressive disorder and substance use disorder. Articles were included if they described interventions targeting both conditions simultaneously; were grounded in cognitive behavioral therapy, motivational interviewing, or motivational enhancement therapy; and were delivered at least in part via digital modalities. In total, 14 studies meeting these criteria were coded using an open-coding approach to identify intervention characteristics and treatment strategies (n=25). Statistical analyses summarized descriptive statistics to capture the frequency and overlap of these strategies. Results: Studies included a range of digital modalities: internet (n=6, 43%), computer (n=3, 21%), smartphone (n=2, 14%), and supportive text messaging interventions (n=3, 21%). Half (n=7, 50%) of the studies included participants with mild to moderate depression symptom severity and hazardous substance use. Only 36% (n=5) of the studies required participants to meet full diagnostic criteria for major depressive disorder for inclusion and 21% (n=3) required a substance use disorder diagnosis. Most interventions targeted adults (n=11, 79%), with few targeting young or emerging adults (n=4, 29%), and only 36% (n=5) reported detailed demographic data. Treatment duration averaged 10.3 (SD 6.8) weeks. Internet-based interventions offered the widest range of treatment strategies (mean 11.7), while supportive text messaging used the fewest (mean 4.6). Common treatment strategies included self-monitoring (n=11, 79%), psychoeducation (n=10, 71%), and coping skills (n=9, 64%). Interventions often combined therapeutic strategies, with psychoeducation frequently paired with self-monitoring (n=9, 64%), assessment (n=7, 50%), coping skills (n=7, 50%), decisional balance (n=7, 50%), feedback (n=7, 50%), and goal setting (n=7, 50%). Conclusions: Among integrated digital interventions for comorbid depression and substance use, there was noteworthy variability in methodology, inclusion criteria, digital modalities, and embedded treatment strategies. Without standardized methods, comparison of the clinical outcomes across studies is challenging. These results emphasize the critical need for future research to adopt standardized approaches to facilitate more accurate comparisons and a clearer understanding of intervention efficacy.
- 9 May 2025
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 12 (1) , e67670
Open AccessDigital Integrated Interventions for Comorbid Depression and Substance Use Disorder: Narrative Review and Content Analysis
Background: Integrated digital interventions for the treatment of comorbid depression and substance use disorder have been developed, and evidence of their effectiveness is mixed. Objective: This study aimed to explore potential reasons for mixed findings in the literature on integrated digital treatments. We described the methodologies and core characteristics of these interventions, identified the presence of evidence-based treatment strategies, examined patterns across digital modalities, and highlighted areas of overlap as well as critical gaps in the existing evidence base. Methods: In June 2024, a literature search was conducted in Google Scholar to identify digital integrated interventions for comorbid major depressive disorder and substance use disorder. Articles were included if they described interventions targeting both conditions simultaneously; were grounded in cognitive behavioral therapy, motivational interviewing, or motivational enhancement therapy; and were delivered at least in part via digital modalities. In total, 14 studies meeting these criteria were coded using an open-coding approach to identify intervention characteristics and treatment strategies (n=25). Statistical analyses summarized descriptive statistics to capture the frequency and overlap of these strategies. Results: Studies included a range of digital modalities: internet (n=6, 43%), computer (n=3, 21%), smartphone (n=2, 14%), and supportive text messaging interventions (n=3, 21%). Half (n=7, 50%) of the studies included participants with mild to moderate depression symptom severity and hazardous substance use. Only 36% (n=5) of the studies required participants to meet full diagnostic criteria for major depressive disorder for inclusion and 21% (n=3) required a substance use disorder diagnosis. Most interventions targeted adults (n=11, 79%), with few targeting young or emerging adults (n=4, 29%), and only 36% (n=5) reported detailed demographic data. Treatment duration averaged 10.3 (SD 6.8) weeks. Internet-based interventions offered the widest range of treatment strategies (mean 11.7), while supportive text messaging used the fewest (mean 4.6). Common treatment strategies included self-monitoring (n=11, 79%), psychoeducation (n=10, 71%), and coping skills (n=9, 64%). Interventions often combined therapeutic strategies, with psychoeducation frequently paired with self-monitoring (n=9, 64%), assessment (n=7, 50%), coping skills (n=7, 50%), decisional balance (n=7, 50%), feedback (n=7, 50%), and goal setting (n=7, 50%). Conclusions: Among integrated digital interventions for comorbid depression and substance use, there was noteworthy variability in methodology, inclusion criteria, digital modalities, and embedded treatment strategies. Without standardized methods, comparison of the clinical outcomes across studies is challenging. These results emphasize the critical need for future research to adopt standardized approaches to facilitate more accurate comparisons and a clearer understanding of intervention efficacy.
- Open Access
- 8 January 2025
- Published by Elsevier in JAACAP Open
- Vol. 3 (4) , 947-958
Substance Use, Suicidal Behavior, and Other Mental Health Outcomes Among Youth With Intersectional Sexual and Gender Diverse Identities
- 8 January 2025
- Published by Elsevier in JAACAP Open
- Vol. 3 (4) , 947-958
Open AccessSubstance Use, Suicidal Behavior, and Other Mental Health Outcomes Among Youth With Intersectional Sexual and Gender Diverse Identities
- Open Access
- 17 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Digital Integrated Interventions for Comorbid Depression and Substance Use Disorder: Narrative Review and Content Analysis (Preprint)
BACKGROUND Integrated digital interventions for the treatment of comorbid depression and substance use disorder have been developed, and evidence of their effectiveness is mixed. OBJECTIVE This study aimed to explore potential reasons for mixed findings in the literature on integrated digital treatments. We described the methodologies and core characteristics of these interventions, identified the presence of evidence-based treatment strategies, examined patterns across digital modalities, and highlighted areas of overlap as well as critical gaps in the existing evidence base. METHODS In June 2024, a literature search was conducted in Google Scholar to identify digital integrated interventions for comorbid major depressive disorder and substance use disorder. Articles were included if they described interventions targeting both conditions simultaneously; were grounded in cognitive behavioral therapy, motivational interviewing, or motivational enhancement therapy; and were delivered at least in part via digital modalities. In total, 14 studies meeting these criteria were coded using an open-coding approach to identify intervention characteristics and treatment strategies (n=25). Statistical analyses summarized descriptive statistics to capture the frequency and overlap of these strategies. RESULTS Studies included a range of digital modalities: internet (n=6, 43%), computer (n=3, 21%), smartphone (n=2, 14%), and supportive text messaging interventions (n=3, 21%). Half (n=7, 50%) of the studies included participants with mild to moderate depression symptom severity and hazardous substance use. Only 36% (n=5) of the studies required participants to meet full diagnostic criteria for major depressive disorder for inclusion and 21% (n=3) required a substance use disorder diagnosis. Most interventions targeted adults (n=11, 79%), with few targeting young or emerging adults (n=4, 29%), and only 36% (n=5) reported detailed demographic data. Treatment duration averaged 10.3 (SD 6.8) weeks. Internet-based interventions offered the widest range of treatment strategies (mean 11.7), while supportive text messaging used the fewest (mean 4.6). Common treatment strategies included self-monitoring (n=11, 79%), psychoeducation (n=10, 71%), and coping skills (n=9, 64%). Interventions often combined therapeutic strategies, with psychoeducation frequently paired with self-monitoring (n=9, 64%), assessment (n=7, 50%), coping skills (n=7, 50%), decisional balance (n=7, 50%), feedback (n=7, 50%), and goal setting (n=7, 50%). CONCLUSIONS Among integrated digital interventions for comorbid depression and substance use, there was noteworthy variability in methodology, inclusion criteria, digital modalities, and embedded treatment strategies. Without standardized methods, comparison of the clinical outcomes across studies is challenging. These results emphasize the critical need for future research to adopt standardized approaches to facilitate more accurate comparisons and a clearer understanding of intervention efficacy.
- 17 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital Integrated Interventions for Comorbid Depression and Substance Use Disorder: Narrative Review and Content Analysis (Preprint)
BACKGROUND Integrated digital interventions for the treatment of comorbid depression and substance use disorder have been developed, and evidence of their effectiveness is mixed. OBJECTIVE This study aimed to explore potential reasons for mixed findings in the literature on integrated digital treatments. We described the methodologies and core characteristics of these interventions, identified the presence of evidence-based treatment strategies, examined patterns across digital modalities, and highlighted areas of overlap as well as critical gaps in the existing evidence base. METHODS In June 2024, a literature search was conducted in Google Scholar to identify digital integrated interventions for comorbid major depressive disorder and substance use disorder. Articles were included if they described interventions targeting both conditions simultaneously; were grounded in cognitive behavioral therapy, motivational interviewing, or motivational enhancement therapy; and were delivered at least in part via digital modalities. In total, 14 studies meeting these criteria were coded using an open-coding approach to identify intervention characteristics and treatment strategies (n=25). Statistical analyses summarized descriptive statistics to capture the frequency and overlap of these strategies. RESULTS Studies included a range of digital modalities: internet (n=6, 43%), computer (n=3, 21%), smartphone (n=2, 14%), and supportive text messaging interventions (n=3, 21%). Half (n=7, 50%) of the studies included participants with mild to moderate depression symptom severity and hazardous substance use. Only 36% (n=5) of the studies required participants to meet full diagnostic criteria for major depressive disorder for inclusion and 21% (n=3) required a substance use disorder diagnosis. Most interventions targeted adults (n=11, 79%), with few targeting young or emerging adults (n=4, 29%), and only 36% (n=5) reported detailed demographic data. Treatment duration averaged 10.3 (SD 6.8) weeks. Internet-based interventions offered the widest range of treatment strategies (mean 11.7), while supportive text messaging used the fewest (mean 4.6). Common treatment strategies included self-monitoring (n=11, 79%), psychoeducation (n=10, 71%), and coping skills (n=9, 64%). Interventions often combined therapeutic strategies, with psychoeducation frequently paired with self-monitoring (n=9, 64%), assessment (n=7, 50%), coping skills (n=7, 50%), decisional balance (n=7, 50%), feedback (n=7, 50%), and goal setting (n=7, 50%). CONCLUSIONS Among integrated digital interventions for comorbid depression and substance use, there was noteworthy variability in methodology, inclusion criteria, digital modalities, and embedded treatment strategies. Without standardized methods, comparison of the clinical outcomes across studies is challenging. These results emphasize the critical need for future research to adopt standardized approaches to facilitate more accurate comparisons and a clearer understanding of intervention efficacy.
- Open Access
Impact of year-long cannabis use for medical symptoms on brain activation during cognitive processes
Importance: Cannabis is increasingly being used to treat medical symptoms, but the effects of cannabis use on brain function in those using cannabis for these symptoms is not known. Objective: To test whether brain activation during working memory, reward, and inhibitory control tasks, areas of cognition impacted by cannabis, showed increases following one year of cannabis use for medical symptoms. Design: This observational cohort study took place from July 2017 to July 2020 and is reported on in 2024. Setting: Participants were from the greater Boston area. Participants: Participants were recruited as part of a clinical trial based on seeking medical cannabis cards for anxiety, depression, pain, or sleep disorders, and were between 18 and 65 years. Exclusion criteria were daily cannabis use and cannabis use disorder at baseline. Main Outcomes and Measures: Outcomes were whole brain functional activation during tasks involving working memory, reward and inhibitory control at baseline and after one year of cannabis use. Results: Imaging was collected in participants before and one year after obtaining medical cannabis cards; 57 at baseline (38 female [66.7%]; mean [SD] age, 38.0 [14.6] years) at baseline, and 54 at one-year (37 female [68.5%]; mean [SD] age, 38.7 [14.3] years). Imaging was also collected in 32 healthy control participants (22 female [68.8%]; mean [SD] age, 33.8 [11.8] years) at baseline. In all groups and at both time points, functional imaging revealed canonical activations of the probed cognitive processes. No statistically significant difference in brain activation between the two timepoints (baseline and one-year) in those with medical cannabis cards and no association of changes in cannabis use frequency with brain activation were found. Conclusions and Relevance: Findings suggest that adults do not show significant neural effects in the areas of cognition of working memory, reward, and inhibitory control after one year of cannabis use for medical symptoms. The results warrant further studies that probe effects of cannabis at higher doses, with greater frequency, in younger age groups, and with larger, more diverse cohorts. Trial Registration: NCT03224468, https://clinicaltrials.gov/ Question: This study investigated the impact of year-long cannabis use for medical symptoms on brain activation during cognitive processes implicated in cannabis use. Findings: Functional magnetic resonance imaging during a working memory, reward, and inhibitory control task was collected at baseline and after one year of medical cannabis card ownership. After one year, brain activation did not differ statistically from baseline and was not associated with changes in cannabis use frequency. Meaning: The absence of activation differences suggests that adults using cannabis for medical conditions may not experience significant neural effects in regards to reward, working memory, or inhibitory control.
Open AccessImpact of year-long cannabis use for medical symptoms on brain activation during cognitive processes
Importance: Cannabis is increasingly being used to treat medical symptoms, but the effects of cannabis use on brain function in those using cannabis for these symptoms is not known. Objective: To test whether brain activation during working memory, reward, and inhibitory control tasks, areas of cognition impacted by cannabis, showed increases following one year of cannabis use for medical symptoms. Design: This observational cohort study took place from July 2017 to July 2020 and is reported on in 2024. Setting: Participants were from the greater Boston area. Participants: Participants were recruited as part of a clinical trial based on seeking medical cannabis cards for anxiety, depression, pain, or sleep disorders, and were between 18 and 65 years. Exclusion criteria were daily cannabis use and cannabis use disorder at baseline. Main Outcomes and Measures: Outcomes were whole brain functional activation during tasks involving working memory, reward and inhibitory control at baseline and after one year of cannabis use. Results: Imaging was collected in participants before and one year after obtaining medical cannabis cards; 57 at baseline (38 female [66.7%]; mean [SD] age, 38.0 [14.6] years) at baseline, and 54 at one-year (37 female [68.5%]; mean [SD] age, 38.7 [14.3] years). Imaging was also collected in 32 healthy control participants (22 female [68.8%]; mean [SD] age, 33.8 [11.8] years) at baseline. In all groups and at both time points, functional imaging revealed canonical activations of the probed cognitive processes. No statistically significant difference in brain activation between the two timepoints (baseline and one-year) in those with medical cannabis cards and no association of changes in cannabis use frequency with brain activation were found. Conclusions and Relevance: Findings suggest that adults do not show significant neural effects in the areas of cognition of working memory, reward, and inhibitory control after one year of cannabis use for medical symptoms. The results warrant further studies that probe effects of cannabis at higher doses, with greater frequency, in younger age groups, and with larger, more diverse cohorts. Trial Registration: NCT03224468, https://clinicaltrials.gov/ Question: This study investigated the impact of year-long cannabis use for medical symptoms on brain activation during cognitive processes implicated in cannabis use. Findings: Functional magnetic resonance imaging during a working memory, reward, and inhibitory control task was collected at baseline and after one year of medical cannabis card ownership. After one year, brain activation did not differ statistically from baseline and was not associated with changes in cannabis use frequency. Meaning: The absence of activation differences suggests that adults using cannabis for medical conditions may not experience significant neural effects in regards to reward, working memory, or inhibitory control.